OTC Markets OTCQB - Delayed Quote
USD
Protagenic Therapeutics, Inc. (PTIX)
0.6380
-0.0080
(-1.24%)
At close: October 30 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2026 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Garo H. Armen Ph.D.
|
Executive Chairman | -- | -- | 1953 |
|
Mr. William Nichols Jr.
|
President | 290.18k | -- | 1975 |
|
Dr. Robert Benjamin Stein M.D., Ph.D.
|
Chief Medical Officer | -- | -- | 1951 |
|
Dr. Andrew Slee Ph.D.
|
Chief Development Officer | -- | -- | 1950 |
Protagenic Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2
Description
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
Corporate Governance
Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
